InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+18.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Alexandre Mérieux, Président exécutif de bioMérieux. Director active across 1 company, notably BIOMERIEUX. Cumulatively, 12 filings have been published. Split: 5 buys · 0 sell. Total volume traded: €248.3m. Activity tracked since 18 November 2024. The latest transaction was disclosed on 30 April 2026 (Acquisition). Regulator: AMF. All data is free.
Companies and markets linked to Alexandre Mérieux
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
779,245 shares@ €69.99720.64% mcap0.5% of flowActionmultiplacesISIN FR00132802862026DD1112483
Canonical exit: 29 Jul 2026 (T+90)
404,367 shares@ €71.9640.34% mcap0.3% of flowActionMultiplacesISIN FR00132802862026DD1112485
Canonical exit: 2 Aug 2026 (T+90)
404,367 shares@ €71.9640.34% mcap0.3% of flowActionMultiplacesISIN FR00132802862026DD1112471
Canonical exit: 2 Aug 2026 (T+90)
779,245 shares@ €69.99720.64% mcap0.5% of flowActionMultiplacesISIN FR00132802862026DD1112475
Canonical exit: 29 Jul 2026 (T+90)
2,152,868 shares@ €1,095.164822.8% of flowActions de Compagnie Mérieux AllianceHors plateforme de négociationISIN FR00132802862025DD1027996
2,152,868 shares@ €1,095.164822.8% of flowActions de CMAHors plateforme de négociationISIN FR00132802862025DD1027997
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de AME HoldingHors plateforme de négociationISIN FR00132802862025DD1013673
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de MHC HoldingHors plateforme de négociationISIN FR00132802862025DD1013681
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de APC HoldingHors plateforme de négociationISIN FR00132802862025DD1013686
2,336,097 shares@ €906.837520.5% of flowActions de Compagnie Mérieux Alliance, AME Holding, MHC Holding et APCHors plateforme de négociationISIN FR00132802862024DD1012649
58,148 shares@ €1,393.04100.0% of flowActions de Compagnie Mérieux AllianceHors plateforme de négociationISIN FR00132802862024DD1006251
Canonical exit: 2 Jan 2025 (T+90)
870,333 shares@ €1,393.0411.7% of flowActions de Compagnie Mérieux AllianceHors plateforme de négociationISIN FR00132802862024DD1006257
12 of 12 declarations
About Alexandre Mérieux
Alexandre Mérieux is a key figure in the governance of bioMérieux, the French specialist in in vitro diagnostics. He currently serves as Executive Chairman of bioMérieux, after having previously held the roles of Chief Executive Officer and, earlier, Chairman and CEO. Following the governance changes implemented in July 2023, he retained a strategic leadership role on the Board, while day-to-day management was entrusted to Pierre Boulud. He is also a long-standing board member of bioMérieux. He holds a degree in biology from Lyon I University and a diploma from HEC Montréal. Before joining bioMérieux, he spent 1999 to 2004 in marketing roles at Silliker Group, working in the United States and Europe, and later as a marketing and business unit director in France. He joined bioMérieux in 2005 as Executive Vice President, Industrial Microbiology. He then led the Industrial Microbiology business from 2005 to 2011, and the Microbiology division from 2011 to 2014. He was appointed Chief Executive Officer in 2014 and became Chairman and CEO in December 2017. His career reflects the continuity of the Mérieux family’s industrial and scientific legacy, but also a progression built on operational management experience. At bioMérieux, he has overseen the strengthening of microbiology activities, the development of higher-value diagnostic solutions, and the execution of an international growth strategy. During his tenure, the company continued to invest in innovation, commercial expansion, and industrial capabilities in a healthcare environment undergoing rapid change. A notable moment in his leadership was the 2023 governance reshaping, designed to separate strategic oversight from executive management more clearly.
